A Cost Analysis of Interstim Therapy

Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency) Clinical Trial

Official title:

Interstim Therapy Retrospective Cost Analysis and Quality of Life

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00200031
• Other study ID #: 4348
• Status: Completed
• Phase: N/A
• First received: September 12, 2005
• Last updated: July 24, 2008
• Start date: July 2005
• Est. completion date: April 2006

Study information

• Verified date: July 2008
• Source: MedtronicNeuro
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

A study to examine the impact that Interstim Therapy for Urinary Control has on health care utilization and costs within a health care system and the satisfaction with treatment expressed by patients using this therapy.

Description:

A retrospective administrative data analysis combined with a prospective health related quality of life/satisfaction with treatment survey designed to examine the impact that Interstim Therapy for Urinary Control has had on health care utilization and costs for the Kaiser Permanente system and the satisfaction with treatment expressed by patients using this therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: April 2006
• Gender: Both
• Age group: 18 Years and older

Eligibility

Patients implanted with an Interstim Therapy for Urinary Control or undergoing test stimulation for potential placement of Interstim Therapy during the period of June 1, 2002 through June 30, 2004 and who are enrolled with Kaiser-Permanente of Southern California.

Study Design

N/A

Related Conditions & MeSH terms

• Urinary Bladder, Overactive
• Urinary Retention
• Urinary Retention and Symptoms of Overactive Bladder (Urge, Frequency)

Intervention

Device:
• Interstim therapy

Locations

Country	Name	City	State
United States	Southern California Permanente Medical Group	Los Angeles	California

Sponsors (1)

Lead Sponsor	Collaborator
MedtronicNeuro

Country where clinical trial is conducted

United States, 

References & Publications (1)

Aboseif SR, Kim DH, Rieder JM, Rhee EY, Menefee SA, Kaswick JR, Ree MH. Sacral neuromodulation: cost considerations and clinical benefits. Urology. 2007 Dec;70(6):1069-73; discussion 1073-4. — View Citation